Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca launches diabetes drug Xigduo in UK
The twice daily tablet ‘Xigduo’ that combines Forxiga (dapagliflozin), a selective and reversible inhibitor of SGLT2, with metformin hydrochloride (HCI), is the first fixed-dose combination of its kind
The twice daily tablet ‘Xigduo’ that combines Forxiga (dapagliflozin), a selective and reversible inhibitor of SGLT2, with metformin hydrochloride (HCI), is the first fixed-dose combination of its kind
With the latest license agreement, Novo Nordisk has exclusive rights to commercialize insulin conjugated to HEPtune and non-exclusive rights to leverage the HEPtune technology across other core therapeutic
According to CureVac, RNActive vaccines represent a novel technology to manufacture safe, efficacious and cost-effective vaccines which are protected against elevated temperature as well as inadvertent freezing. RNActive
Through the collaboration, the companies identified a novel lead series of pan-metallo beta-lactamase inhibitors, which in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates while exhibiting
According to Bayer, Adempas is currently the only treatment approved for use in two rare types of pulmonary hypertension (PH) – PAH and chronic thromboembolic pulmonary hypertension (CTEPH).
Temple University is the original owner of the RHB-102 patents. Previously RedHill Biopharma had reported that Scolr Pharma, which originally licensed certain patents to RedHill Biopharma for RHB-102,
No dose-limiting safety issues and no serious adverse events have been reported in the dose-escalation stage. Based on these encouraging safety and tolerability results, BioLineRx will proceed with
Obtained in a collaborative project with the US-based Paragon Bioservices, the data showed that CAP cells were able to produce very high titers of RSV. When compared to
The DSMC met to review available patient data as part of the planned interim analysis, scheduled to occur following 222 patient events. The DSMC, following its review, recommended
C3 Jian’s C16G2 is a synthetic peptide derived from the company’s pheromone signaling platform technology referred to as STAMPs (specifically targeted antimicrobial peptides). The drug targets the specific